FORTUNE 500

• Revenues, Profits
• Profits as % of...
• EPS, Total return, Employees

			REVENUES		PROFITS
Rank	Company	Fortune 1000 rank	$ millions	% change from 2007	$ millions	% change from 2007
1	Johnson & Johnson	29	63,747.0	4.3	12,949.0	22.4
2	Pfizer	46	48,296.0	-0.3	8,104.0	-0.5
3	Abbott Laboratories	80	29,527.6	13.9	4,880.7	35.3
4	Merck	103	23,850.3	-1.4	7,808.4	138.4
5	Wyeth	110	22,833.9	1.9	4,417.8	-4.3
6	Bristol-Myers Squibb	120	21,366.0	7.0	5,247.0	142.4
7	Eli Lilly	122	20,378.0	9.4	-2,071.9	-170.2
8	Schering-Plough	138	18,502.0	45.8	1,903.0	N.A.
9	Amgen	168	15,003.0	1.6	4,196.0	32.5
10	Gilead Sciences	444	5,335.8	26.1	2,011.2	24.5
11	Mylan	462	5,137.6	92.7	-181.2	N.A.
12	Genzyme	502	4,605.0	20.8	421.1	-12.3
13	Allergan	517	4,403.4	11.2	578.6	15.9
14	Biogen Idec	546	4,097.5	29.2	783.2	22.7
15	Forest Laboratories	569	3,836.3	11.5	967.9	113.2
16	Hospira	597	3,629.5	5.6	320.9	134.6
17	Watson Pharmaceuticals	769	2,535.5	1.6	238.4	69.0
18	Celgene	830	2,254.8	60.4	-1,533.7	-777.3
19	NBTY	852	2,179.5	8.2	153.2	-26.3
20	Cephalon	903	1,974.6	11.4	222.5	N.A.
21	Perrigo	958	1,822.1	25.9	135.8	84.0

Rank	Company	Revenues %	Assets %	Stockholders' Equity %
1	Johnson & Johnson	20.3	15.2	30.5
2	Pfizer	16.8	7.3	14.1
3	Abbott Laboratories	16.5	11.5	27.9
4	Merck	32.7	16.5	41.6
5	Wyeth	19.3	10.0	23.0
6	Bristol-Myers Squibb	24.6	17.8	42.9
7	Eli Lilly	-10.2	-7.1	-30.8
8	Schering-Plough	10.3	6.8	18.1
9	Amgen	28.0	11.5	20.6
10	Gilead Sciences	37.7	28.7	48.4
11	Mylan	-3.5	-1.7	-6.7
12	Genzyme	9.1	4.9	5.8
13	Allergan	13.1	8.5	14.4
14	Biogen Idec	19.1	9.2	13.5
15	Forest Laboratories	25.2	21.4	26.1
16	Hospira	8.8	6.3	18.1
17	Watson Pharmaceuticals	9.4	6.5	11.3
18	Celgene	-68.0	-34.5	-43.9
19	NBTY	7.0	7.9	15.3
20	Cephalon	11.3	7.0	14.8
21	Perrigo	7.5	5.3	14.5

		EARNINGS PER SHARE	TOTAL RETURN TO INVESTORS		EMPLOYEES
Rank	Company	1998-2008 Annual growth (%)	1998-2008 Annual rate (%)	2008 (%)	Number	% change from 2007
1	Johnson & Johnson	15.2	5.6	-7.8	118,700	-0.4
2	Pfizer	3.5	-5.7	-16.7	81,800	-5.5
3	Abbott Laboratories	7.5	3.7	-2.6	68,838	0.2
4	Merck	5.4	-5.2	-45.7	55,200	-6.3
5	Wyeth	5.9	-2.0	-12.7	47,426	-6.1
6	Bristol-Myers Squibb	5.4	-6.2	-7.3	35,000	-16.7
7	Eli Lilly	N.A.	-5.4	-21.3	40,500	-0.2
8	Schering-Plough	-1.0	-9.7	-35.2	51,000	-7.3
9	Amgen	16.9	8.2	24.4	16,800	-3.7
10	Gilead Sciences	N.A.	34.9	11.1	3,441	17.0
11	Mylan	N.A.	-2.8	-29.7	13,500	12.5
12	Genzyme	7.3	10.5	-10.8	11,000	10.0
13	Allergan	N.A.	10.5	-37.0	8,740	10.8
14	Biogen Idec	24.3	19.8	-16.3	4,704	9.4
15	Forest Laboratories	39.5	6.7	-30.1	5,211	1.7
16	Hospira	N.A.	N.A.	-37.1	14,500	3.6
17	Watson Pharmaceuticals	4.7	-8.3	-2.1	5,070	-10.1
18	Celgene	N.A.	45.7	19.6	2,441	44.9
19	NBTY	15.3	8.2	-42.9	13,760	27.4
20	Cephalon	N.A.	24.0	7.4	2,780	-0.6
21	Perrigo	N.A.	14.5	-7.1	6,200	0.0